Cargando…
The Therapy of Pulmonary Fibrosis in Paracoccidioidomycosis: What Are the New Experimental Approaches?
Pulmonary fibrosis (PF) is considered the most important sequela developed in patients suffering from the chronic form of paracoccidioidomycosis (PCM), which leads to the loss of respiratory function in 50% of cases; this residual pulmonary abnormality is present even after antifungal treatment. To...
Autor principal: | González, Ángel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712212/ https://www.ncbi.nlm.nih.gov/pubmed/33050568 http://dx.doi.org/10.3390/jof6040217 |
Ejemplares similares
-
Combined Silymarin and Cotrimoxazole Therapy Attenuates Pulmonary Fibrosis in Experimental Paracoccidioidomycosis
por: Resende, Victor Quinholes, et al.
Publicado: (2022) -
Paracoccidioidomycosis: What We Know and What Is New in Epidemiology, Diagnosis, and Treatment
por: Peçanha, Paulo Mendes, et al.
Publicado: (2022) -
Diagnosis and Treatment of Pulmonary Coccidioidomycosis and Paracoccidioidomycosis
por: Peçanha-Pietrobom, Paula Massaroni, et al.
Publicado: (2023) -
Pentoxifylline immunomodulation in the treatment of experimental chronic pulmonary paracoccidioidomycosis
por: Lopera, Damaris Elena, et al.
Publicado: (2015) -
Pulmonary and cerebral paracoccidioidomycosis
por: Machado, Matheus Garcia Lago, et al.
Publicado: (2022)